No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score–matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)

BACKGROUND: Extended interval dosing of natalizumab is associated with significantly lower progressive multifocal leukoencephalopathy risk compared with every-4-week (Q4W) dosing in patients with relapsing-remitting multiple sclerosis. Previous studies have suggested that natalizumab effectiveness i...

Descripción completa

Detalles Bibliográficos
Autores principales: Butzkueven, Helmut, Kappos, Ludwig, Spelman, Tim, Trojano, Maria, Wiendl, Heinz, Su, Ray, Liao, Shirley, Hyde, Robert, Licata, Stephanie, Ho, Pei-Ran, Campbell, Nolan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481711/
https://www.ncbi.nlm.nih.gov/pubmed/34603507
http://dx.doi.org/10.1177/17562864211042458

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481711/
https://www.ncbi.nlm.nih.gov/pubmed/34603507
http://dx.doi.org/10.1177/17562864211042458

Ejemplares similares